Phoenix Financial Ltd. cut its stake in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) by 46.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,518 shares of the company’s stock after selling 7,534 shares during the quarter. Phoenix Financial Ltd.’s holdings in VanEck Pharmaceutical ETF were worth $932,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also bought and sold shares of the stock. TD Waterhouse Canada Inc. boosted its holdings in VanEck Pharmaceutical ETF by 130.0% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 230 shares of the company’s stock worth $25,000 after acquiring an additional 130 shares during the last quarter. Latitude Advisors LLC bought a new position in VanEck Pharmaceutical ETF in the 3rd quarter valued at $55,000. Fifth Third Bancorp raised its position in VanEck Pharmaceutical ETF by 357.1% in the third quarter. Fifth Third Bancorp now owns 512 shares of the company’s stock worth $56,000 after acquiring an additional 400 shares during the period. IFP Advisors Inc lifted its stake in VanEck Pharmaceutical ETF by 115.7% in the second quarter. IFP Advisors Inc now owns 537 shares of the company’s stock valued at $59,000 after purchasing an additional 288 shares during the last quarter. Finally, North Star Investment Management Corp. purchased a new position in shares of VanEck Pharmaceutical ETF during the 3rd quarter valued at $64,000.
VanEck Pharmaceutical ETF Stock Down 0.9%
NASDAQ PPH opened at $121.59 on Tuesday. The company has a market cap of $1.09 billion, a PE ratio of 29.81 and a beta of 0.43. The firm’s 50-day simple moving average is $113.80 and its two-hundred day simple moving average is $108.77. VanEck Pharmaceutical ETF has a 52 week low of $97.52 and a 52 week high of $124.17.
VanEck Pharmaceutical ETF Cuts Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Stockholders of record on Thursday, October 1st were given a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 1.2%. This is a drop from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248. The ex-dividend date was Thursday, October 1st.
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Stories
- Five stocks we like better than VanEck Pharmaceutical ETF
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
